Advertisement
Screener

Acurx Pharmaceuticals, Inc. (ACXP) Form PRE 14A: Preliminary proxy statement

Acurx Pharmaceuticals, Inc. Form PRE 14A: Preliminary proxy statement

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2025-07-24: Form PRE 14A; Period of report 2025-09-16; Description PRE 14A; Document tm2521566-1_pre14a.htm.
  • 2025-05-19: Form PRE 14A; Period of report 2025-07-17; Description PRE 14A; Document tm252476-1_pre14a.htm.
  • 2023-04-17: Form PRE 14A; Period of report 2023-06-15; Description PRE 14A; Document tm232131-1_pre14a.htm.
FiledFormPeriod of reportDescriptionDocument
2025-07-24PRE 14A2025-09-16PRE 14Atm2521566-1_pre14a.htm
2025-05-19PRE 14A2025-07-17PRE 14Atm252476-1_pre14a.htm
2023-04-17PRE 14A2023-06-15PRE 14Atm232131-1_pre14a.htm

Similar stocks

Stock NameCountryMarket CapPE Ratio
SYNLOGIC, INC. (SYBX)United States$0.007B
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
EXICURE, INC. (XCUR)United States$0.008B-1.54
Pulmatrix, Inc. (PULM)United States$0.006B